updated 8/30/2010 9:17:23 AM ET 2010-08-30T13:17:23

TEL AVIV, Israel, Aug. 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced its initiation of early stage activities to enter requests for regulatory approvals, required for every Medical Device. The approvals will be for clinical trials and marketing qualifications. The qualifications to be requested at this early stage will include FDA approvals, CE approvals for marketing in the EU, and being recognized by Reimbursement programs.

Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers. mBeach expects to receive the initial approvals, for clinical trials mainly, by mid 2011. These requested clinical trial approvals, follow the clinical trials conducted by mBeach wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS"), in Israel, with the Ministry of health, Medical Device qualification Department and the international Helsinki approval for conducting clinical trials.

mBeach CEO Yossi Biderman commented, "The early stage regulatory approach, adopted by mBeach, is due to the lengthy regulatory procedures. We expect the approvals to be staggered over a two year period, unless facing unforeseeable obstacles. These requested and required approvals form a basic component in the heath and marketing strategy defined by mBeach. This will help mBeach achieve its two major goals of improving quality of life for millions of people around the world and will greatly increase shareholder value. These approvals combined with a growing market demand and technical innovative approach, will have on the final product what we think will be a boosting impact. We expect our SkinScan 650, a non-invasive, point-of-care, doctors decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution."

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com .

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com